US District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit
Portfolio Pulse from Benzinga Newsdesk
The U.S. District Court for the District of Delaware ruled in favor of Sarepta Therapeutics, granting summary judgment on invalidity in a patent infringement lawsuit filed by REGENXBIO Inc. and the University of Pennsylvania. The patent in question, used by Sarepta to produce SRP-9001 for Duchenne muscular dystrophy treatment, was exclusively licensed to REGENXBIO by Penn. REGENXBIO plans to appeal the decision, which does not affect its current licenses or therapeutic pipeline.
January 08, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
REGENXBIO Inc. lost a patent infringement lawsuit but will appeal. The ruling does not affect its current licenses or pipeline.
While the court ruling is negative, REGENXBIO's statement that the decision does not impact its current licenses or pipeline may mitigate short-term negative impact on the stock price. The intention to appeal also indicates the case is not yet fully resolved.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Sarepta Therapeutics received a favorable court ruling in a patent infringement case related to its Duchenne muscular dystrophy treatment.
Sarepta's favorable court ruling may positively influence investor sentiment in the short term, as it removes a legal hurdle for the company's Duchenne muscular dystrophy treatment production.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70